Federated Hermes’s AgomAb Therapeutics NV AGMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.9M Sell
1,614,014
-3,986
-0.2% -$51.6K 0.03% 514
2026
Q2
$21M Hold
1,618,000
– – 0.03% 487
2026
Q1
$17M Buy
+1,618,000
New +$22.9M 0.03% 510

Other funds holding AGMB

Federated Hermes's AGMB Position: Q3 2026 in Review

Federated Hermes reduced its AgomAb Therapeutics NV (AGMB) stake by 0.25% in Q3 2026, selling an estimated $51.6K and leaving 1,614,014 shares worth $17.9M. The position accounts for 0.03% of the portfolio, ranked #514.

Federated Hermes first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. The position peaked at $21M in Q2 2026. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • Federated Hermes held 1,614,014 shares of AgomAb Therapeutics NV worth $17.9M as of Q3 2026.
  • Federated Hermes sold 3,986 AgomAb Therapeutics NV shares in Q3 2026, an estimated $51.6K.
  • AgomAb Therapeutics NV made up 0.03% of Federated Hermes's portfolio in Q3 2026, its #514 holding.
  • Federated Hermes first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
  • Federated Hermes's AgomAb Therapeutics NV position peaked at $21M in Q2 2026.
  • 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on Federated Hermes's 13F filing for Q3 2026, filed 12 Nov 2026.